The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery
暂无分享,去创建一个
Brian D. Marsden | Wen Hwa Lee | Frank von Delft | Opher Gileadi | Claire Strain-Damerell | Anthony R. Bradley | C. Bountra | F. von Delft | W. Yue | E. Carpenter | O. Gileadi | A. Bullock | B. Marsden | N. Burgess-Brown | M. Fairhead | C. Strain-Damerell | Alex N. Bullock | Chas Bountra | A. Echalier | Michael Fairhead | W. H. Lee | Aude Echalier | Paul Brennan | Nicola A. Burgess-Brown | Elisabeth P. Carpenter | Wyatt Yue | A. Bradley | Paul Brennan
[1] Edward W. Lowe,et al. Computational Methods in Drug Discovery , 2014, Pharmacological Reviews.
[2] J. Ng,et al. Gentle, fast and effective crystal soaking by acoustic dispensing , 2016, bioRxiv.
[3] John P. Overington,et al. The druggable genome and support for target identification and validation in drug development , 2016, Science Translational Medicine.
[4] Daniel Svozil,et al. Probes &Drugs portal: an interactive, open data resource for chemical biology , 2017, Nature Methods.
[5] Eddy Arnold,et al. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery. , 2014, Progress in biophysics and molecular biology.
[6] Nathan Brown,et al. Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.
[7] Sebastian Kelm,et al. A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density , 2017, Nature Communications.
[8] Christopher W Murray,et al. Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). , 2016, Angewandte Chemie.
[9] Andrew D. Johnson,et al. Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair , 2015, Nature Genetics.
[10] D. Waugh,et al. Escherichia coli maltose‐binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused , 1999, Protein science : a publication of the Protein Society.
[11] G. Franck. Open access , 2012, Cell cycle.
[12] Harren Jhoti,et al. Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.
[13] Alexandre Varnek,et al. Estimation of the size of drug-like chemical space based on GDB-17 data , 2013, Journal of Computer-Aided Molecular Design.
[14] Jean-Louis Reymond,et al. Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17 , 2012, J. Chem. Inf. Model..
[15] U. H. Danielson,et al. Biophysics in drug discovery: impact, challenges and opportunities , 2016, Nature Reviews Drug Discovery.
[16] Patrick Collins,et al. The XChemExplorer graphical workflow tool for routine or large-scale protein–ligand structure determination , 2017, Acta crystallographica. Section D, Structural biology.
[17] Julian Blagg,et al. Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology , 2017, Cancer cell.
[18] Paul E Brennan,et al. Chemical probes and inhibitors of bromodomains outside the BET family† †The authors declare no competing interests. , 2016, MedChemComm.
[19] Peter M Visscher,et al. Large-scale genomics unveils the genetic architecture of psychiatric disorders , 2014, Nature Neuroscience.
[20] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[21] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[22] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.
[23] Brian D. Marsden,et al. High-throughput production of human proteins for crystallization: The SGC experience , 2010, Journal of structural biology.
[24] Frank von Delft,et al. A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc03115j , 2015, Chemical science.
[25] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.